Archives

by in
Entry Author Date Location
East Coast Biotech Roundup: Yumanity, Padlock, CAR-T Fever, & More 12/19/14 Boston
Houston’s Bellicum Pharma Rides T-Cell Therapy Wave to $140M IPO 12/18/14 Texas
ASH Roundup: Immunotherapy Stars, Gene Therapy Leaps Ahead 12/11/14 San Francisco
More Biotechs Belly-Up These Days but Dendreon Still “One of a Kind” 12/02/14 National
Juno, Less Than a Year Old, Lines up IPO to Fund Cancer Work 11/17/14 Seattle
Try Then Buy? Sutro Deal Could Be Celgene’s Biggest Antibody Bet Yet 10/23/14 New York
East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More 10/16/14 Boston
John Maraganore: From “Prototypical Geek” To Canny Alnylam Chief 09/07/14 Boston
ARCH Venture Exploits IPO Window To Raise $400M Fund, Its Eighth 08/27/14 Seattle
With $310M and Public Investors Aboard, Is a Juno IPO Next? 08/05/14 Seattle
East Coast Biotech Roundup: Acceleron, Seres, Sage, & More 07/18/14 Boston
How a Little Serendipity Led Acceleron to a Crippling Blood Disease 07/17/14 Boston
East Coast Biotech Roundup: Regeneron, Sarepta, Jounce, & More 07/11/14 Boston
West Coast Biotech Roundup: Seragon, Ambrx, Pregenen, and More 07/03/14 San Diego
East Coast Biotech Roundup: Bluebird, Moderna, Navitor, & More 06/20/14 Boston
Bluebird’s Gene Therapy Quickly Halts Blood Disease in Small Study 06/14/14 Boston
East Coast Biotech Roundup: LTI, SolveBio, Proteon, & More 05/16/14 Boston
Two San Francisco Startups Sharing In Third Rock’s Rich Third Fund 04/24/14 San Francisco
AAVLife Gets $12M to Bring Gene Therapy to Rare Ataxia 04/15/14 Boston
East Coast Biotech Roundup: Neurophage, Boston Biotech, Insmed, & More 03/28/14 Boston
East Coast Biotech Roundup: Voyager, Concert, Retrophin, & More 02/14/14 Boston
Third Rock’s Voyager Hunts For CNS Disorders With Gene Therapy 02/12/14 Boston
Gene Therapy Lurches Ahead, Sees Thorny Future Questions on Price 01/27/14 National
Celgene Plunks Down $177M Upfront for OncoMed’s Stem Cell Drugs 12/03/13 San Francisco
Dimension, Backed by Fidelity, Targets Hemophilia With Gene Therapy 10/31/13 Boston
Sage Therapeutics Nabs $20M Series B From Third Rock, Arch 10/16/13 Boston
David Schenkein, Cancer Doc Turned CEO, Aims to Build New Genentech 10/16/13 Boston
East Coast Life Sciences Roundup: Verdine, Ariad, Karyopharm, & More 10/11/13 Boston
Boston’s Life Science Disruptors: The Photos 10/07/13 Boston
9 Takeaways from Boston’s Life Science Disruptors 10/04/13 Boston
Page 1 of 3 next page »